Suppr超能文献

组胺H2受体在哮喘气道中的新作用。

A new role for histamine H2-receptors in asthmatic airways.

作者信息

Jackson P J, Manning P J, O'Byrne P M

机构信息

Department of Medicine, McMaster University Health Sciences Center, Hamilton, Ontario, Canada.

出版信息

Am Rev Respir Dis. 1988 Oct;138(4):784-8. doi: 10.1164/ajrccm/138.4.784.

Abstract

Histamine tachyphylaxis develops with repeated inhalation of histamine in asthmatic subjects, and this appears to be due to the release of inhibitory prostaglandins. The purpose of this study was to determine whether histamine H2-receptors are also involved in the development of this protective effect in the airways. Seven subjects with mild asthma were studied on 2 days separated by at least 1 wk. On both days, three histamine inhalation tests were performed, separated by 1 h. The response was expressed as the provocative concentration of histamine causing a 20% decrease in FEV1 (histamine PC20). Before each study day subjects were pretreated with placebo or cimetidine (300 mg twice a day) for 3 days in a double-blind, randomized, crossover study. Cimetidine pretreatment had no effect on either baseline FEV1 or on baseline histamine PC20 (p = 0.461). After pretreatment with placebo, histamine tachyphylaxis occurred in all subjects; the mean PC20 increased from 3.01 mg/ml (%SD, 1.44) to 4.88 mg/ml (%SD, 1.68) and to 6.84 mg/ml (%SD, 1.68). Cimetidine pretreatment prevented histamine tachyphylaxis; the mean PC20 was 2.72 mg/ml (%SD, 1.77), 3.03 mg/ml (%SD, 1.73), and 3.56 mg/ml (%SD, 1.59) with repeated tests. These values differed significantly from placebo for both the second (p = 0.014) and third (p = 0.001) tests. This study demonstrated that cimetidine pretreatment prevents histamine tachyphylaxis and suggests that histamine tachyphylaxis occurs through stimulation of histamine H2-receptors in the airway.

摘要

在哮喘患者中,反复吸入组胺会出现组胺快速减敏现象,这似乎是由于抑制性前列腺素的释放所致。本研究的目的是确定组胺H2受体是否也参与气道中这种保护作用的形成。对7名轻度哮喘患者进行了研究,研究在至少间隔1周的2天进行。在这两天中,均进行了3次组胺吸入试验,每次试验间隔1小时。反应以引起第一秒用力呼气容积(FEV1)降低20%的组胺激发浓度(组胺PC20)表示。在每项研究日前,在一项双盲、随机、交叉研究中,受试者接受安慰剂或西咪替丁(300mg,每日2次)预处理3天。西咪替丁预处理对基线FEV1或基线组胺PC20均无影响(p = 0.461)。安慰剂预处理后,所有受试者均出现组胺快速减敏现象;平均PC20从3.01mg/ml(%标准差,1.44)增至4.88mg/ml(%标准差,1.68),再增至6.84mg/ml(%标准差,1.68)。西咪替丁预处理可防止组胺快速减敏现象;重复试验时,平均PC20分别为2.72mg/ml(%标准差,1.77)、3.03mg/ml(%标准差,1.73)和3.56mg/ml(%标准差,1.59)。第二次(p = 0.014)和第三次(p = 0.001)试验时,这些值与安慰剂相比有显著差异。本研究表明,西咪替丁预处理可防止组胺快速减敏现象,并提示组胺快速减敏现象是通过刺激气道中的组胺H2受体而发生的。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验